Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in lung adenocarcinoma

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3601-3610

  Ruiz Morales, José Manuel ^a   Dorantes Heredia, Rita ^a   Arrieta, Oscar ^b   Chávez Tapia, Norberto C ^b   Motola Kuba, Daniel ^a  

^a LIVER RESEARCH UNIT   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Adenocarcinoma; Lepidic; Lipocalin; Matrix metalloproteinase

Indexed keywords

CARBOPLATIN; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PACLITAXEL; PEMETREXED; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ADENOCARCINOMA; AGED; BIOSYNTHESIS; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ACUTE-PHASE PROTEINS; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOCALINS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS;

EID: 84929962353     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2997-3     Document Type: Article

References (49)

1. GLOBOCAN. International Agency for Research on Cancer. Cancer incidence and mortality worldwide in 2012. Globocan cancer fact sheets: lung cancer 2014. http://globocan.iarc.fr/. Accessed 17 June 2012.
2. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol Off Publ Int Assoc Stud Lung Cancer. 2007;2(8):706–14. doi:10.1097/JTO.0b013e31812f3c1a.
3. National Comprehensive Cancer Network. Occult primary (version 1.2015). 2014. http://www.nccn.org/professionals/physician_gls/pdf/occult.pdf. Accessed 28 Oct 2014.
4. Nesbitt JC, Putnam Jr JB, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 1995;60(2):466–72.
5. Wenners AS, Mehta K, Loibl S, Park H, Mueller B, Arnold N, et al. Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer. PLoS One. 2012;7(10):e45826. doi:10.1371/journal.pone.0045826.
6. Kaur S, Chakraborty S, Baine MJ, Mallya K, Smith LM, Sasson A, et al. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One. 2013;8(2):e55171. doi:10.1371/journal.pone.0055171.
7. Barresi V, Reggiani-Bonetti L, Di Gregorio C, Vitarelli E, Ponz De Leon M, Barresi G. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathol Res Pract. 2011;207(8):479–86. doi:10.1016/j.prp.2011.05.012.
8. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012;1826(1):129–69. doi:10.1016/j.bbcan.2012.03.008.
9. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(15):5390–5. doi:10.1158/1078-0432.CCR-04-2391.
10. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007;7(10):778–90. doi:10.1038/nrc2190.
11. Villalba Caloca J, Martínez Heredero R. Frecuencia del carcinoma broncopulmonar en pacientes fumadores y no fumadores diagnosticados en el Instituto Nacional de Enfermedades Respiratorias en el año 2001. Rev Inst Nac Enferm Respiratorias. 2004;17:27–34.
12. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109(1):120–9.
13. Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group. J Thorac Cardiovasc Surg. 1987;94(3):349–54.
14. Harpole Jr DH, Herndon 2nd JE, Young Jr WG, Wolfe WG, Sabiston Jr DC. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer. 1995;76(5):787–96.
15. Lipford 3rd EH, Eggleston JC, Lillemoe KD, Sears DL, Moore GW, Baker RR. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol. 1984;8(5):357–65.
16. Ruffini E, Asioli S, Filosso PL, Buffoni L, Bruna MC, Mossetti C, et al. Significance of the presence of microscopic vascular invasion after complete resection of Stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-size categories: did the 2009 7th edition of the TNM staging system miss something? J Thorac Oncol Off Publ Int Assoc Stud Lung Cancer. 2011;6(2):319–26. doi:10.1097/JTO.0b013e3182011f70.
17. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997;45(1):17–23. doi:10.1006/geno.1997.4896.
18. Bratt T. Lipocalins and cancer. Biochim Biophys Acta. 2000;1482(1–2):318–26.
19. Flower DR. The lipocalin protein family: structure and function. Biochem J. 1996;318(Pt 1):1–14.
20. Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000;39(8):1935–41.
21. Zhao H, Konishi A, Fujita Y, Yagi M, Ohata K, Aoshi T, et al. Lipocalin 2 bolsters innate and adaptive immune responses to blood-stage malaria infection by reinforcing host iron metabolism. Cell Host Microbe. 2012;12(5):705–16. doi:10.1016/j.chom.2012.10.010.
22. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. 2008;108(3):389–97. doi:10.1007/s10549-007-9619-3.
23. Shinriki S, Jono H, Ueda M, Obayashi K, Nakamura T, Ota K, et al. Stromal expression of neutrophil gelatinase-associated lipocalin correlates with poor differentiation and adverse prognosis in oral squamous cell carcinoma. Histopathology. 2014;64(3):356–64. doi:10.1111/his.12293.
24. Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget. 2014;5(6):1576–94.
25. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005;169(4):681–91. doi:10.1083/jcb.200409115.
26. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 2010;288(1):10–6. doi:10.1016/j.canlet.2009.05.027.
27. Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, et al. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res. 2013;5(5):481–96.
28. Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, et al. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer. 2009;9:390. doi:10.1186/1471-2407-9-390.
29. Dic A. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors. Oncol Lett. 2013;5(5):1677–81. doi:10.3892/ol.2013.1252.
30. Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, Harikumar KB, et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008;68(15):6100–8. doi:10.1158/0008-5472.can-08-0540.
31. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;276(40):37258–65. doi:10.1074/jbc.M106089200.
32. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009;100(1):9–16. doi:10.1111/j.1349-7006.2008.01001.x.
33. Cao L, Yang H, Hu C. The expression and its clinical significance of MMP-2 and MMP-9 in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi = Chin J Lung Cancer. 2003;6(6):484–7. doi:10.3779/j.issn. 1009-3419.2003.06.18.
34. Iniesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C, et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep. 2007;17(1):217–23.
35. Liu Z, Xu S, Xiao N, Song C, Zhang H, Li F. Overexpression of IL-8 and MMP-9 confer high malignant phenotype in patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi = Chin J Lung Cancer. 2010;13(8):795–802. doi:10.3779/j.issn. 1009-3419.2010.08.09.
36. Ramanujum R, Lin YL, Liu JK, He S. Regulatory expression of MMP-8/MMP-9 and inhibition of proliferation, migration and invasion in human lung cancer A549 cells in the presence of HGF variants. Kaohsiung J Med Sci. 2013;29(10):530–9. doi:10.1016/j.kjms.2013.01.011.
37. Rollin J, Regina S, Vourc'h P, Iochmann S, Blechet C, Reverdiau P, et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer. 2007;56(2):273–80. doi:10.1016/j.lungcan.2006.11.021.
38. Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A, Rath M. Modulation of MMP-2 and MMP-9 by cytokines, mitogens and inhibitors in lung cancer and malignant mesothelioma cell lines. Oncol Rep. 2009;22(6):1283–91.
39. Schveigert D, Cicenas S, Bruzas S, Samalavicius NE, Gudleviciene Z, Didziapetriene J. The value of MMP-9 for breast and non-small cell lung cancer patients’ survival. Adv Med Sci. 2013;58(1):73–82. doi:10.2478/v10039-012-0066-y.
40. Wang JL, Wu DW, Cheng ZZ, Han WZ, Xu SW, Sun NN. Expression of High Mobility Group Box - B1 (HMGB-1) and Matrix Metalloproteinase-9 (MMP-9) in Non-small Cell Lung Cancer (NSCLC). Asian Pac J Cancer Prev APJCP. 2014;15(12):4865–9.
41. Zheng S, Chang Y, Hodges KB, Sun Y, Ma X, Xue Y, et al. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res. 2010;30(3):713–8.
42. O'Sullivan S, Medina C, Ledwidge M, Radomski MW, Gilmer JF. Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance—NO and MMP-9 interactions. Biochim Biophys Acta. 2014;1843(3):603–17. doi:10.1016/j.bbamcr.2013.12.006.
43. Chang CK, Hung WC, Chang HC. The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. J Cell Mol Med. 2008;12(6B):2781–9. doi:10.1111/j.1582-4934.2008.00215.x.
44. Zheng R, Qin X, Li W, Kang J. Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells. Zhongguo Fei Ai Za Zhi = Chin J Lung Cancer. 2011;14(1):13–7. doi:10.3779/j.issn. 1009-3419.2011.01.03.
45. Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, et al. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Stud Lung Cancer. 2014;9(9):1385–92. doi:10.1097/jto.0000000000000238.
46. Zhang XF, Zhang Y, Zhang XH, Zhou SM, Yang GG, Wang OC, et al. Clinical significance of Neutrophil gelatinase-associated lipocalin(NGAL) expression in primary rectal cancer. BMC Cancer. 2009;9:134. doi:10.1186/1471-2407-9-134.
47. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Investig J Tech Methods Pathol. 2009;89(5):531–48. doi:10.1038/labinvest.2009.17.
48. Buss JL, Greene BT, Turner J, Torti FM, Torti SV. Iron chelators in cancer chemotherapy. Curr Top Med Chem. 2004;4(15):1623–35.
49. Jones DT, Trowbridge IS, Harris AL. Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res. 2006;66(5):2749–56. doi:10.1158/0008-5472.can-05-3857.